Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in neutrophils | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 17 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress GAB2 in microglia; measure IL-1β and TNF release and surface HLA-DR and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of GAB2 in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- GAB2 in dopamine neurons, braak-0.51 (p 0.160) → -0.89 (p 0.001)receipt 14388
- GAB2 in microglia, braak+0.29 (p 0.449) → +0.63 (p 0.067)receipt 14387
Swarm cases
receipt 14388: GAB2 in dopamine neurons, braak
- power
- full sample -0.63 (p 0.0053, n 18), 95% CI -0.85 to -0.23. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.69 (p 0.0016, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.69 (p 0.0016, n 18). not the mix.
- skeptic
- leave-one-out range -0.72 to -0.58, sign flips 0; without severely affected donors -0.63 (p 0.0053, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GAB2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 14387: GAB2 in microglia, braak
- power
- full sample +0.36 (p 0.148, n 18), 95% CI -0.13 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.148, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.38 (p 0.118, n 18). could be the mix.
- skeptic
- leave-one-out range +0.26 to +0.48, sign flips 0; without severely affected donors +0.36 (p 0.148, n 18). fragile.
- cell type
- strongest in dopamine neurons: -0.63 (p 0.0053, n 18) vs +0.36 in microglia. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GAB2 in microglia.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GAB2 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.50 p 0.076 (needs p < 1.6e-4)
Receipts
loading the receipts